{"organizations": [], "uuid": "c9a7d948d53b0bbe68c39b16dc291158c87d2594", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180212.html", "section_title": "Archive News &amp; Video for Monday, 12 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-magforce-says-receives-fda-investi/brief-magforce-says-receives-fda-investigational-device-exemption-approval-idUSASM000J69", "country": "US", "domain_rank": 408, "title": "BRIEF-Magforce Says Receives FDA Investigational Device Exemption Approval", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-02-12T14:42:00.000+02:00", "replies_count": 0, "uuid": "c9a7d948d53b0bbe68c39b16dc291158c87d2594"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-magforce-says-receives-fda-investi/brief-magforce-says-receives-fda-investigational-device-exemption-approval-idUSASM000J69", "ord_in_thread": 0, "title": "BRIEF-Magforce Says Receives FDA Investigational Device Exemption Approval", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "fda investigational device exemption approval feb", "sentiment": "negative"}, {"name": "magforce ag", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 12 (Reuters) - MAGFORCE AG:\n* SAID ON SATURDAY RECEIVED FDA INVESTIGATIONAL DEVICE EXEMPTION APPROVAL TO CONDUCT A CLINICAL TRIAL WITH NANOTHERM THERAPY AS FOCAL ABLATION TREATMENT FOR INTERMEDIATE RISK PROSTATE CANCER Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-12T14:42:00.000+02:00", "crawled": "2018-02-13T15:53:25.023+02:00", "highlightTitle": ""}